Guidant gains FDA OK for peripheral cardiac stent:
This article was originally published in Clinica
The US FDA has approved for sale Guidant's AGILTRAC 0.018 peripheral dilatation catheter for treating patients with peripheral vascular disease (PVD). The device, which is also CE-marked for sale in Europe, is inserted through a small incision to treat blockages in peripheral arteries through a non-surgical, angioplasty procedure. The Indianapolis, Indiana firm said that PVD, a condition that is characterised by blockages in vessels supplying the kidneys and limbs, affects an estimated 10 million patients in the US.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.